Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

terminated233%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886
terminatedphase_2

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

NCT03325296
terminatedphase_1

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

NCT02936492
completedphase_2

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

NCT01300052
completedphase_2

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

NCT00755196
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01536886Phase 2

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Completed
NCT03325296Phase 2

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Terminated
NCT02936492Phase 1

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Terminated
NCT01300052Phase 2

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Completed
NCT00755196Phase 2

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Completed
NCT00645164Phase 1

Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6